Zetagen Therapeutics Shares In-vivo Dose Optimization Data of ZetaMAST™ (Zeta-MBC-005) Metastatic Breast Cancer in Liver
(Patients with disseminated metastatic disease from breast cancer are likely to have liver involvement in >50% of cases at some point during disease progression.)
- Zetagen identifies two concentrations of Zeta-MBC-005 which were most effective in treating metastatic breast cancer in the liver
- Zeta-MBC-005 showed a significant decrease in tumor volume (4-fold) vs. control Doxorubicin
- Zeta-MBC-005 demonstrated an increased survival rate (3.9-fold) over control with no lung metastases.
SYRACUSE, N.Y.–(BUSINESS WIRE)–Central New York Biotech Accelerator (CNYBAC) — Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, minimizing patient side effects with the potential to increase survival rates, announced today in-vivo results of their dose optimization study of ZetaMAST™ (Zeta-MBC-005). Zetagen identified two concentrations of Zeta-MBC-005 which demonstrated superior effectiveness, reduction in tumor burden, and increased survival rate over control Doxorubicin.
